Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Dexcom Inc (DXCM) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Dexcom Inc. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1093557.
Total stock buying since 2014: $1,746,350.
Total stock sales since 2014: $785,755,539.
Total stock option exercises since 2014: $16,751,908.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 177,442 | $13,869,196 | 0 | $0 |
| 2024 | 0 | $0 | 290,565 | $37,445,869 | 0 | $0 |
| 2023 | 0 | $0 | 239,577 | $27,218,371 | 0 | $0 |
| 2022 | 0 | $0 | 76,614 | $22,696,065 | 0 | $0 |
| 2021 | 0 | $0 | 299,457 | $128,341,957 | 0 | $0 |
| 2020 | 0 | $0 | 438,604 | $143,140,207 | 20,385 | $199,543 |
| 2019 | 0 | $0 | 427,888 | $64,727,520 | 30,603 | $153,065 |
| 2018 | 0 | $0 | 576,502 | $64,666,028 | 197,834 | $1,158,125 |
| 2017 | 35,000 | $1,746,350 | 364,657 | $27,002,321 | 208,503 | $1,718,699 |
| 2016 | 0 | $0 | 1,234,804 | $98,963,335 | 387,003 | $2,212,500 |
| 2015 | 0 | $0 | 2,059,653 | $157,458,815 | 1,352,001 | $11,309,976 |
| 2014 | 0 | $0 | 7,500 | $225,855 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2016-10-10 | Valdes Jorge A (CTO) | Option Ex | 11,000 | 7.63 | 83,930 |
| 2016-10-05 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 5,000 | 82.55 | 412,750 |
| 2016-09-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 93.97 | 298,999 |
| 2016-09-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 10,300 | 94.00 | 968,200 |
| 2016-09-22 | Roper Jess (SVP, CFO) | Sale | 2,470 | 93.99 | 232,155 |
| 2016-09-21 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 5,000 | 92.87 | 464,365 |
| 2016-09-14 | Sayer Kevin R (President & CEO) | Sale | 7,000 | 91.79 | 642,530 |
| 2016-09-12 | Kahn Barbara (Director) | Sale | 5,000 | 92.90 | 464,510 |
| 2016-09-12 | Valdes Jorge A (CTO) | Sale | 7,071 | 92.06 | 650,963 |
| 2016-09-12 | Skyler Jay S (Director) | Sale | 10,000 | 93.00 | 930,000 |
| 2016-09-09 | Lister John (General Manager, EMEA) | Sale | 7,120 | 93.65 | 666,780 |
| 2016-09-09 | Valdes Jorge A (CTO) | Sale | 12,000 | 93.66 | 1,123,908 |
| 2016-09-09 | Valdes Jorge A (CTO) | Option Ex | 12,000 | 7.63 | 91,560 |
| 2016-09-09 | Skyler Jay S (Director) | Sale | 25,000 | 94.07 | 2,351,800 |
| 2016-09-08 | Gregg Terrance H (Executive Chairman) | Sale | 5,145 | 95.59 | 491,831 |
| 2016-09-07 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 4,999 | 94.45 | 472,155 |
| 2016-09-07 | Balo Andrew K (EVP, Clinical and Regulatory) | Option Ex | 4,999 | 3.19 | 15,946 |
| 2016-09-07 | Foletta Mark G (Director) | Sale | 1,800 | 94.62 | 170,325 |
| 2016-09-07 | Gregg Terrance H (Executive Chairman) | Sale | 5,595 | 95.01 | 531,569 |
| 2016-09-01 | Lord Jonathan T Md (Director) | Sale | 10,000 | 91.50 | 915,000 |
| 2016-08-30 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 92.14 | 921,360 |
| 2016-08-24 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 5,000 | 91.72 | 458,600 |
| 2016-08-24 | Balo Andrew K (EVP, Clinical and Regulatory) | Option Ex | 5,000 | 3.19 | 15,950 |
| 2016-08-24 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 92.72 | 927,150 |
| 2016-08-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 90.89 | 289,224 |
| 2016-08-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 10,300 | 90.74 | 934,591 |
| 2016-08-23 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 91.11 | 911,120 |
| 2016-08-22 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 90.51 | 905,110 |
| 2016-08-19 | Gregg Terrance H (Executive Chairman) | Sale | 20,000 | 90.63 | 1,812,520 |
| 2016-08-19 | Skyler Jay S (Director) | Sale | 25,000 | 90.77 | 2,269,225 |
| 2016-08-19 | Altman Steven R (Director) | Sale | 3,500 | 90.91 | 318,178 |
| 2016-08-18 | Gregg Terrance H (Executive Chairman) | Sale | 20,000 | 90.77 | 1,815,320 |
| 2016-08-15 | Sayer Kevin R (President & CEO) | Sale | 7,000 | 90.78 | 635,474 |
| 2016-08-15 | Gregg Terrance H (Executive Chairman) | Sale | 14,942 | 91.01 | 1,359,856 |
| 2016-08-12 | Lord Jonathan T Md (Director) | Sale | 5,000 | 90.50 | 452,505 |
| 2016-08-11 | Gregg Terrance H (Executive Chairman) | Sale | 10,900 | 91.03 | 992,281 |
| 2016-08-11 | Lord Jonathan T Md (Director) | Sale | 5,000 | 90.78 | 453,895 |
| 2016-08-10 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 5,000 | 90.26 | 451,300 |
| 2016-08-10 | Balo Andrew K (EVP, Clinical and Regulatory) | Option Ex | 5,000 | 3.19 | 15,950 |
| 2016-08-09 | Lister John (General Manager, EMEA) | Sale | 3,560 | 91.07 | 324,216 |
| 2016-08-09 | Valdes Jorge A (CTO) | Sale | 32,000 | 91.06 | 2,913,984 |
| 2016-08-09 | Valdes Jorge A (CTO) | Option Ex | 32,000 | 7.63 | 244,160 |
| 2016-08-09 | Sayer Kevin R (President & CEO) | Sale | 20,000 | 90.98 | 1,819,560 |
| 2016-08-09 | Sayer Kevin R (President & CEO) | Option Ex | 20,000 | 8.79 | 175,799 |
| 2016-08-09 | Gregg Terrance H (Executive Chairman) | Sale | 37,168 | 91.05 | 3,384,220 |
| 2016-08-08 | Kahn Barbara (Director) | Sale | 6,000 | 90.52 | 543,132 |
| 2016-08-08 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 4 | 11.33 | 45 |
| 2016-08-05 | Valdes Jorge A (CTO) | Sale | 25,000 | 91.22 | 2,280,375 |
| 2016-08-05 | Valdes Jorge A (CTO) | Option Ex | 25,000 | 9.80 | 245,000 |
| 2016-08-05 | Gregg Terrance H (Executive Chairman) | Sale | 20,000 | 91.29 | 1,825,800 |
| 2016-08-01 | Moy Jeffrey (SVP, Operations) | Sale | 10,000 | 93.00 | 930,000 |
| 2016-07-29 | Moy Jeffrey (SVP, Operations) | Sale | 5,000 | 91.00 | 455,000 |
| 2016-07-27 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 5,000 | 88.14 | 440,700 |
| 2016-07-27 | Balo Andrew K (EVP, Clinical and Regulatory) | Option Ex | 5,000 | 3.19 | 15,950 |
| 2016-07-25 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 3,182 | 87.31 | 277,820 |
| 2016-07-25 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 10,300 | 87.33 | 899,478 |
| 2016-07-22 | Moy Jeffrey (SVP, Operations) | Sale | 10,000 | 88.48 | 884,800 |
| 2016-07-19 | Moy Jeffrey (SVP, Operations) | Sale | 12,843 | 84.00 | 1,078,812 |
| 2016-07-13 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 5,000 | 80.12 | 400,600 |
| 2016-07-13 | Balo Andrew K (EVP, Clinical and Regulatory) | Option Ex | 5,000 | 3.19 | 15,950 |
| 2016-07-13 | Sayer Kevin R (President & CEO) | Sale | 7,000 | 79.92 | 559,454 |
| 2016-07-11 | Lister John (General Manager, EMEA) | Sale | 3,560 | 79.35 | 282,493 |
| 2016-07-11 | Valdes Jorge A (CTO) | Sale | 32,000 | 79.36 | 2,539,552 |
| 2016-07-11 | Valdes Jorge A (CTO) | Option Ex | 32,000 | 7.63 | 244,160 |
| 2016-06-29 | Moy Jeffrey (SVP, Operations) | Sale | 4,557 | 80.00 | 364,560 |
| 2016-06-29 | Balo Andrew K (EVP, Clinical and Regulatory) | Sale | 5,000 | 78.10 | 390,500 |
| 2016-06-29 | Balo Andrew K (EVP, Clinical and Regulatory) | Option Ex | 5,000 | 3.19 | 15,950 |
| 2016-06-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 10,300 | 77.40 | 797,189 |
| 2016-06-20 | Moy Jeffrey (SVP, Operations) | Sale | 14,418 | 77.00 | 1,110,186 |
| 2016-06-20 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 110,000 | 75.00 | 8,250,000 |
| 2016-06-20 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 110,000 | 3.19 | 350,900 |
| 2016-06-20 | Sayer Kevin R (President & CEO) | Sale | 70,000 | 75.00 | 5,250,000 |
| 2016-06-09 | Lister John (General Manager, EMEA) | Sale | 3,560 | 73.27 | 260,855 |
| 2016-06-09 | Moy Jeffrey (SVP, Operations) | Sale | 6,910 | 74.00 | 511,340 |
| 2016-06-09 | Valdes Jorge A (CTO) | Sale | 10,000 | 73.72 | 737,150 |
| 2016-06-09 | Valdes Jorge A (CTO) | Option Ex | 10,000 | 7.79 | 77,900 |
| 2016-06-08 | Moy Jeffrey (SVP, Operations) | Sale | 6,866 | 71.00 | 487,486 |
| 2016-06-08 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 18,239 | 70.88 | 1,292,798 |
| 2016-06-08 | Valdes Jorge A (CTO) | Sale | 8,038 | 70.00 | 562,660 |
| 2016-06-07 | Roper Jess (SVP, CFO) | Sale | 3,471 | 69.00 | 239,499 |
| 2016-05-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,674 | 63.59 | 106,446 |
| 2016-05-18 | Valdes Jorge A (CTO) | Sale | 20,000 | 61.75 | 1,234,940 |
| 2016-05-18 | Valdes Jorge A (CTO) | Option Ex | 20,000 | 9.80 | 196,000 |
| 2016-05-16 | Gregg Terrance H (Executive Chairman) | Sale | 20,000 | 62.72 | 1,254,360 |
| 2016-05-12 | Kahn Barbara (Director) | Sale | 3,000 | 60.73 | 182,175 |
| 2016-05-11 | Gregg Terrance H (Executive Chairman) | Sale | 23,600 | 64.41 | 1,520,725 |
| 2016-05-09 | Lister John (General Manager, EMEA) | Sale | 3,560 | 62.50 | 222,500 |
| 2016-05-09 | Gregg Terrance H (Executive Chairman) | Sale | 12,168 | 61.94 | 753,685 |
| 2016-04-27 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 2,361 | 70.39 | 166,190 |
| 2016-04-27 | Valdes Jorge A (CTO) | Sale | 10,000 | 70.00 | 700,000 |
| 2016-04-25 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,666 | 69.15 | 115,205 |
| 2016-04-25 | Roper Jess (SVP, CFO) | Sale | 3,471 | 69.00 | 239,499 |
| 2016-04-12 | Lister John (General Manager, EMEA) | Sale | 3,704 | 65.78 | 243,649 |
| 2016-04-11 | Gregg Terrance H (Executive Chairman) | Sale | 2,169 | 68.00 | 147,492 |
| 2016-04-04 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 20,600 | 70.62 | 1,454,772 |
| 2016-04-04 | Valdes Jorge A (CTO) | Sale | 20,000 | 70.08 | 1,401,579 |
| 2016-04-04 | Valdes Jorge A (CTO) | Option Ex | 20,000 | 7.79 | 155,800 |
| 2016-03-31 | Roper Jess (SVP, CFO) | Sale | 3,470 | 69.00 | 239,430 |
| 2016-03-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,666 | 61.76 | 102,893 |
| 2016-03-22 | Gregg Terrance H (Executive Chairman) | Sale | 25,000 | 59.51 | 1,487,750 |
| 2016-03-14 | Lister John (General Manager, EMEA) | Sale | 3,560 | 63.75 | 226,964 |
| 2016-03-07 | Kahn Barbara (Director) | Sale | 5,000 | 67.04 | 335,215 |
| 2016-02-18 | Lister John (Sr. VP, General Counsel) | Sale | 3,560 | 62.50 | 222,500 |
| 2016-01-25 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,666 | 73.34 | 122,182 |
| 2016-01-25 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 10,300 | 73.24 | 754,372 |
| 2016-01-22 | Roper Jess (SVP, CFO) | Sale | 3,518 | 72.97 | 256,701 |
| 2016-01-20 | Sayer Kevin R (President & CEO) | Sale | 7,000 | 75.00 | 525,000 |
| 2016-01-12 | Valdes Jorge A (CTO) | Sale | 5,610 | 80.17 | 449,725 |
| 2016-01-11 | Valdes Jorge A (CTO) | Sale | 1,641 | 78.43 | 128,710 |
| 2016-01-08 | Lister John (Sr. VP, General Counsel) | Sale | 3,560 | 82.57 | 293,934 |
| 2015-12-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,666 | 82.22 | 136,978 |
| 2015-12-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 14,000 | 82.26 | 1,151,598 |
| 2015-12-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 14,000 | 10.56 | 147,910 |
| 2015-12-22 | Roper Jess (SVP, CFO) | Sale | 3,417 | 81.19 | 277,415 |
| 2015-12-17 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 7,500 | 82.52 | 618,870 |
| 2015-12-17 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 7,500 | 3.19 | 23,925 |
| 2015-12-15 | Gregg Terrance H (Executive Chairman) | Sale | 15,000 | 83.26 | 1,248,885 |
| 2015-12-14 | Lister John (Sr. VP, General Counsel) | Sale | 3,560 | 82.50 | 293,682 |
| 2015-12-09 | Valdes Jorge A (CTO) | Sale | 10,000 | 85.58 | 855,800 |
| 2015-12-09 | Valdes Jorge A (CTO) | Option Ex | 10,000 | 7.52 | 75,200 |
| 2015-12-08 | Lister John (Sr. VP, General Counsel) | Sale | 2,476 | 87.17 | 215,820 |
| 2015-12-04 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 86.79 | 867,870 |
| 2015-12-04 | Gregg Terrance H (Executive Chairman) | Option Ex | 10,000 | 6.85 | 68,500 |
| 2015-12-03 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 7,500 | 86.37 | 647,782 |
| 2015-12-03 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 7,500 | 3.19 | 23,925 |
| 2015-12-02 | Gregg Terrance H (Executive Chairman) | Sale | 10,000 | 87.05 | 870,530 |
| 2015-12-02 | Gregg Terrance H (Executive Chairman) | Option Ex | 10,000 | 6.85 | 68,500 |
| 2015-11-30 | Gregg Terrance H (Executive Chairman) | Sale | 5,000 | 86.50 | 432,500 |
| 2015-11-30 | Gregg Terrance H (Executive Chairman) | Option Ex | 5,000 | 6.85 | 34,250 |
| 2015-11-25 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 7,500 | 87.49 | 656,190 |
| 2015-11-25 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 7,500 | 3.19 | 23,925 |
| 2015-11-25 | Gregg Terrance H (Executive Chairman) | Sale | 15,000 | 87.53 | 1,312,905 |
| 2015-11-25 | Gregg Terrance H (Executive Chairman) | Option Ex | 15,000 | 6.85 | 102,750 |
| 2015-11-24 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 4,800 | 86.36 | 414,532 |
| 2015-11-24 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 4,800 | 3.19 | 15,312 |
| 2015-11-24 | Gregg Terrance H (Executive Chairman) | Sale | 15,497 | 86.54 | 1,341,110 |
| 2015-11-24 | Gregg Terrance H (Executive Chairman) | Option Ex | 15,497 | 6.85 | 106,154 |
| 2015-11-23 | Doubleday Richard (EVP, Chief Commercial Officer) | Sale | 1,666 | 85.85 | 143,024 |
| 2015-11-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Sale | 14,000 | 85.84 | 1,201,788 |
| 2015-11-23 | Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) | Option Ex | 14,000 | 9.80 | 137,200 |
| 2015-11-23 | Balo Andrew K (EVP, Clinical, Regulatory) | Sale | 5,200 | 86.50 | 449,800 |
| 2015-11-23 | Balo Andrew K (EVP, Clinical, Regulatory) | Option Ex | 5,200 | 3.19 | 16,588 |
| 2015-11-20 | Gregg Terrance H (Executive Chairman) | Sale | 21,903 | 86.48 | 1,894,171 |
| 2015-11-20 | Gregg Terrance H (Executive Chairman) | Option Ex | 21,903 | 6.85 | 150,035 |
| 2015-11-19 | Gregg Terrance H (Executive Chairman) | Sale | 100 | 85.50 | 8,550 |
| 2015-11-19 | Gregg Terrance H (Executive Chairman) | Option Ex | 100 | 6.85 | 685 |
| 2015-11-18 | Roper Jess (SVP, CFO) | Sale | 7,000 | 84.36 | 590,492 |
| 2015-11-18 | Roper Jess (SVP, CFO) | Option Ex | 6,000 | 9.80 | 58,800 |
| 2015-11-16 | Gregg Terrance H (Executive Chairman) | Sale | 15,000 | 83.48 | 1,252,275 |
| 2015-11-13 | Gregg Terrance H (Executive Chairman) | Sale | 5,000 | 85.10 | 425,485 |
Insider trading activities including stock purchases, stock sales, and option exercises of DXCM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Dexcom Inc (symbol DXCM, CIK number 1093557) see the Securities and Exchange Commission (SEC) website.